How'd you fix Pear Therapeutics's revenue issues in 2026?
Direct Answer To fix Pear Therapeutics's 2026 revenue issues, a successor must pivot from failed payer-reimbursement to a B2B2C model: direct-pay subscriptions, employer-EAP bundling at $5-8 PEPM, and white-label licensing of FDA-cleared re…
Read full answer ↗